Aspire Biopharma Holdings, Inc. (ASBP) Fair Value 2026

ASBP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (38/100)

Quick Summary — As of 2026-08-28, Aspire Biopharma Holdings, Inc. (ASBP) trades at $8.51. QOC: 5.5/10. Value Trap Risk: 38/100 (LOW). 0/13 models active.

Key Facts

Ticker
ASBP
Price
$8.51
Quality Score
5.5/10
Value Trap Risk
38/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give ASBP?

0 Intrinsic Value Models vs. Current Price ($8.51)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Aspire Biopharma Holdings, Inc. (ASBP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Aspire Biopharma Holdings, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ASBP?

0 of 13 models are currently active for ASBP. See which stocks rank higher →

How Does ASBP Rank in Biotechnology?

Among 625 Biotechnology stocks, ASBP ranks #213 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Aspire Biopharma Holdings, Inc.'s positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.

Is ASBP a Value Trap?

CirclFi's Value Trap algorithm assigns ASBP a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Aspire Biopharma Holdings, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Aspire Biopharma Holdings, Inc. earns a quality score of 5.5/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ASBP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Aspire Biopharma Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

LSTALisata Therapeutics, Inc.QOC 5.5SPRYARS Pharmaceuticals, Inc.QOC 5.5ADXNAddex Therapeutics LtdQOC 5.5LENZLENZ Therapeutics, Inc.QOC 5.5PCVXVaxcyte, Inc.QOC 5.5ABVXABIVAX Société AnonymeQOC 5.5INTIInhibitor Therapeutics, Inc.QOC 4.8TENXTenax Therapeutics, Inc.QOC 4.1PLXProtalix BioTherapeutics, Inc.QOC 6.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: LSTA · SPRY · ADXN · LENZ · PCVX · ABVX · INTI · TENX · PLX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ASBP?

6 companies across all industries closest to ASBP’s Quality of Company score of 5.5/10.

INUVInuvo, Inc.QOC 5.5PIACPrinceton Capital CorporationQOC 5.5AURAurora Innovation, Inc.QOC 5.5ALMAlmonty Industries Inc.QOC 5.5BGLCBioNexus Gene Lab Corp.QOC 5.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: INUV · PIAC · AUR · ALM · BGLC · NVDA

Where Does ASBP Sit in CirclFi's Biotechnology Rankings?

ASBP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Aspire Biopharma Holdings, Inc.’s Valuation?

What is Aspire Biopharma Holdings, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Aspire Biopharma Holdings, Inc. (ASBP). The Quality of Company score is 5.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ASBP overvalued or undervalued right now?

At $8.51, 0 of 0 active models suggest ASBP may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Aspire Biopharma Holdings, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.5 mean for ASBP?

Aspire Biopharma Holdings, Inc.'s QOC of 5.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ASBP?

CirclFi analyzes ASBP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ASBP a value trap in 2026?

Aspire Biopharma Holdings, Inc.'s Value Trap score is 38/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Aspire Biopharma Holdings, Inc. (ASBP) a Quality of Company score of 5.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ASBP/ · Methodology
Primary sources for this ASBP valuation
  • Financial statements: Aspire Biopharma Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001847345) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ASBP as of ; valuations recomputed .